The Baveno VIII Consensus Conference (March 2026, Baveno, Italy) updated clinical guidance for advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases across nine expert panels, building on evidence since the Baveno VII conference.
272 statements and recommendations achieved strong consensus (>80% faculty agreement), covering non-invasive risk stratification in compensated ACLD, steatotic liver disease modifiers, prevention of first and further decompensation, portal hypertensive bleeding management, cirrhosis recompensation, Budd-Chiari syndrome, PSVD/NCPF, and portal vein thrombosis; CSPH cutoffs were revised and pediatric guidance was added for the first time.
Consensus-based guidance reflects expert opinion and voting rather than direct trial data; recommendations depend heavily on the quality of the underlying evidence reviewed by each panel, which is not individually graded in the abstract.
Clinicians managing cirrhosis and portal hypertension should update their practice to reflect revised CSPH cutoffs and expanded non-invasive test thresholds from Baveno VIII. First-ever pediatric-specific recommendations and guidance on cirrhosis recompensation are now available as part of this framework.
Explore related topics
